Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Oct 4;30(1):91.
doi: 10.1186/1756-9966-30-91.

Platinum Resistance in Breast and Ovarian Cancer Cell Lines

Affiliations
Free PMC article
Review

Platinum Resistance in Breast and Ovarian Cancer Cell Lines

Niels Eckstein. J Exp Clin Cancer Res. .
Free PMC article

Abstract

Breast and ovarian cancers are among the 10 leading cancer types in females with mortalities of 15% and 6%, respectively. Despite tremendous efforts to conquer malignant diseases, the war on cancer declared by Richard Nixon four decades ago seems to be lost. Approximately 21,800 women in the US will be diagnosed with ovarian cancer in 2011. Therefore, its incidence is relatively low compared to breast cancer with 207.090 prognosed cases in 2011. However, overall survival unmasks ovarian cancer as the most deadly gynecological neoplasia. Platinum-based chemotherapy is emerging as an upcoming treatment modality especially in triple negative breast cancer. However, in ovarian cancer Platinum-complexes for a long time are established as first line treatment. Emergence of a resistant phenotype is a major hurdle in curative cancer therapy approaches and many scientists around the world are focussing on this issue. This review covers new findings in this field during the past decade.

Figures

Figure 1
Figure 1
Structure formulas of platinum-complexes. Cisplatin, Carboplatin, and Oxaliplatin. Cis- and Carboplatin show high degree of cross-resistance, while oxaliplatin resistance seems to follow a different mechanism of action, showing only partial or no cross-resistance to Cis- and Carboplatin.
Figure 2
Figure 2
Schematic model of Amphiregulin signalling. Amphiregulin induced signaling of the EGFR/ERBB2 receptor tyrosine kinases in Cisplatin resistant MCF-7 cells.

Similar articles

See all similar articles

Cited by 30 articles

See all "Cited by" articles

References

    1. Metzger-Filho O, Moulin C, D'Hondt V. First-line systemic treatment of ovarian cancer: a critical review of available evidence and expectations for future directions. Curr Opin Oncol. 2010;22:513–20. doi: 10.1097/CCO.0b013e32833ae99c. - DOI - PubMed
    1. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–67. doi: 10.1172/JCI45014. - DOI - PMC - PubMed
    1. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10:515–27. doi: 10.1016/j.ccr.2006.10.008. - DOI - PMC - PubMed
    1. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nature Reviews Drug Discovery. 2005;4:307–20. doi: 10.1038/nrd1691. - DOI - PubMed
    1. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol. 2007;63:12–31. doi: 10.1016/j.critrevonc.2007.02.001. - DOI - PubMed

Publication types

Substances

Feedback